Asymmetric peptide dendrimers are effective linkers for antibody-mediated delivery of diverse payloads to b cells in vitro and in vivo

Pharmaceutical Research

Volumn 31, Issue 11, 2014, Pages 3150-3160

  Shah, Neha D ^a   Parekh, Harendra S ^a   Steptoe, Raymond J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

B cell; Dendrimer DNA; Monoclonal antibody; Targeting

Indexed keywords

ANTIBODY; DENDRIMER; DNA; PEPTIDE;

B LYMPHOCYTE; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; PLASMID; PROCEDURES;

ANTIBODIES; B-LYMPHOCYTES; DENDRIMERS; DNA; DRUG DELIVERY SYSTEMS; PEPTIDES; PLASMIDS;

EID: 84932115461     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-014-1408-1     Document Type: Article

References (24)

1. Svenson S, Tomalia DA. Dendrimers in biomedical applications-reflections on the field. Adv Drug Deliv Rev. 2005;57(15):2106-29.
2. Astruc D, Boisselier E, Ornelas C. Dendrimers designed for functions: from physical, photophysical, and supramolecular properties to applications in sensing, catalysis, molecular electronics, photonics, and nanomedicine. Chem Rev. 2010;110(4):1857-959.
3. Boas U, Heegaard PM. Dendrimers in drug research. Chem Soc Rev. 2004;33(1):43-63.
4. Parekh HS. The advance of dendrimers-a versatile targeting platform for gene/drug delivery. Curr Pharm Des. 2007;13(27):2837-50.
5. Duncan R, Izzo L. Dendrimer biocompatibility and toxicity. Adv Drug Deliv Rev. 2005;57(15):2215-37.
6. Shukla R, Thomas TP, Peters JL, Desai AM, Kukowska-Latallo J, Patri AK, et al. HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb. Bioconjug Chem. 2006;17(5):1109-15.
7. Patri AK, Myc A, Beals J, Thomas TP, Bander NH, Baker JRJ. Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy. Bioconjug Chem. 2004;15(6):1174-81.
8. Kobayashi H, Sato N, Saga T, Nakamoto Y, Ishimat IT, Toyama S. Monoclonal antibody-dendrimer conjugates enable radiolabeling of antibody with markedly high specific activity with minimal loss of immunoreactivity. Eur J Nucl Med. 2000;29(9):1334-9.
9. Shah N, Steptoe RJ, Parekh HS. Low generation asymmetric dendrimers with minimal toxicity effectively complex DNA. J Peptide Sci. 2011;17:470-8.
10. Sarin VK, Kent SBH, Tam JP, Merrifield RB. Quantitative monitoring of solid-phase peptide synthesis by the ninhydrin reaction. Anal Biochem. 1981;117:147-57.
11. Coffman RL. Surface antigen expression and immunoglobulin gene rearrangement during mouse pre-B cell development. Immunol Rev. 1983;69:5-23.
12. Krop I, de Fougerolles AR, Hardy RR, Allison M, Schlissel MS, Fearon DT. Self-renewal of B-1 lymphocytes is dependent on CD19. Eur J Immunol. 1996;26:238-42.
13. Smith E, Roberts K, Hutchings A, Galfre G. Monoclonal antibodies to the major structural glycoprotein of the Chlamydomonas cell wall. Planta. 1984;161:330-8.
14. Steptoe RJ, Ritchie JM, Wilson NS, Villadangos JA, Lew AM, Harrison LC. Cognate CD4+ help elicited by resting dendritic cells does not impair the induction of peripheral tolerance in CD8+ T cells. J Immunol. 2007;178(4):2094-103.
15. Liu H, May K. Disulfide bond structures of IgG molecules: structural variations, chemical modifications and possible impacts to stability and biological function. MAbs. 2012;4(1):17-23.
16. McNally A, McNally M, Galea R, Thomas R, Steptoe RJ. Immunogenic, but not steady-state, antigen presentation permits regulatory T-cells to control CD8+ T-cell effector differentiation by IL-2 modulation. PLOSOne. 2014;9(1):e85455.
17. Liu H, Chumsae C, Gaza-Bulseco G, Hurkmans K, Radziejewski CH. Ranking the susceptibility of disulfide bonds in human IgG1 antibodies by reduction, differential alkylation, and LC-MS analysis. Anal Chem. 2010;82(12):5219-126.
18. Kumar P, Ban HS, Kim SS, Wu H, Pearson T, Greiner DL, et al. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell. 2008;134(4):577-86.
19. Mahnke K, Qian Y, Knop J, Enk AH. Induction of CD4+/CD25+ regulatory T cells by targeting of antigens to immature dendritic cells. Blood. 2003;101:4862-9.
20. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol. 2005;23:1147-57.
21. Weiner LM, Surana R, Wang S. Monoclonal antibodies: Versatile platforms for cancer immunotherapy. Nat Rev Immunol. 2010;10:317-27.
22. Zhu Z, Shi X. Dendrimer-based nanodevices for targeted drug delivery applications. J Mater Chem B: Materials for Biology and Medicine. 2013;1:4199-211.
23. Oliveira S, Heukers R, Sornkom J, Kok RJ, an Bergen en Henegouwen PMP. Targeting tumors with nanobodies for cancer imaging and therapy. J Controlled Release. 2013;172:607 - 17.
24. Majidi J, Barar J, Baradaran B, Abdolalizadeh J, Omidi Y. Target therapy of cancer: Implementation of monoclonal antibodies and nanobodies. Human Antibodies. 2009;18.